ArriVent BioPharma has dosed the first patient in a global Phase 3 study that could reshape first-line treatment for a small ...
16.0 months median progression-free survival (mPFS) with firmonertinib indicates strong efficacy in first-line patients with EGFR PACC mutant non-small cell lung cancer (NSCLC). Robust central nervous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback